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Abstract
The binding characteristics of [125I]insulin-like growth factor
(IGF)-I were studied in human brain and pituitary gland.
Competition binding studies with DES(1-3)IGF-I and R3-IGF-I,
which display high affinity for the IGF-I receptor and low
affinity for IGF binding proteins (IGFBPs), were performed to
distinguish [125I]IGF-I binding to IGF-I receptors and IGFBPs.
Specific [125I]IGF-I binding in brain regions and the posterior
pituitary was completely displaced by DES(1-3)IGF-I and
R3-IGF-I, indicating binding to IGF-I receptors. In contrast,
[125I]IGF-I binding in the anterior pituitary was not displaced by
DES(1-3)IGF-I and R3-IGF-I, suggesting binding to an IGF-
binding site that is different from the IGF-I receptor. Binding
affinity of IGF-I to this site was about 10-fold lower than for the
IGF-I receptor. Using western immunoblotting we were also
unable to detect IGF-I receptors in human anterior pituitary.
Instead, western immunoblotting and immunoprecipitation
experiments showed a 150-kDa IGFBP-3-acid labile subunit
(ALS) complex in the anterior pituitary and not in the posterior
pituitary and other brain regions. RT-PCR experiments
showed the expression of ALS mRNA in human anterior
pituitary indicating that the anterior pituitary synthesizes ALS.
In the brain regions and posterior pituitary, IGFBP-3 was
easily washed away during pre-incubation procedures as
used in the [125I]IGF-I binding experiments. In contrast, the
IGFBP-3 complex in the anterior pituitary could not be
removed by these washing procedures. Our results indicate
that the human anterior pituitary contains a not previously
described tightly cell membrane-bound 150-kDa IGFBP-3–
ALS complex that is absent in brain and posterior pituitary.
Keywords: acid labile subunit, human brain, IGFBP-3,
insulin-like growth factor binding proteins, insulin-like growth
factor I, pituitary gland.
J. Neurochem. (2002) 82, 430–438.
The insulin-like growth factor (IGF) system comprises two
IGFs (IGF-I and IGF-II), IGF-I and IGF-II receptors, and at
least six distinct insulin-like growth factor binding proteins
(IGFBPs) (Spagnoli and Rosenfeld 1997). In the central
nervous system, IGF-I and IGF-II support the growth and
differentiation of neurons and glial cells (Baskin et al. 1988;
D’Ercole et al. 1996). The distribution of IGF-I and IGF-II
receptors have been studied in both rodent and human brains
(Bohannon et al. 1988; Lesniak et al. 1988; Kar et al. 1993;
De Keyser et al. 1994; Wilczak et al. 2000). The IGF-I
receptor is a heterotetrameric glycoprotein composed of two
a and two b subunits linked by disulphide bounds (D’Ercole
et al. 1996). The IGF-II receptor is a monomeric receptor
with a striking extracellular domain made up almost
exclusively of 15 cysteine-based repeats, and is identical to
the cation-independent mannose-6-phosphate receptor (Mor-
gan et al. 1987; Kornfeld 1992). IGFBPs play a crucial role
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in transporting IGFs in the circulation, cerebrospinal ﬂuid,
and across the capillary barrier to the target cells (Baxter
1994; Rosenfeld et al. 1999). IGFBP-3 and IGFBP-5, in
addition to binding IGFs, also can associate with an acid-
labile subunit (ALS), thereby further increasing the half-life
of the IGFs (Twigg and Baxter 1998; Twigg et al. 1998).
IGFBPs are also present at the level of the extracellular
matrix or cell surface, where they can either enhance or
inhibit the presentation of IGFs to their receptors (Spagnoli
and Rosenfeld 1997; Clemmons 1998; Rechler and Clem-
mons 1998; Hwa et al. 1999). In addition, some of the
IGFBPs, such as IGFBP-3, are also capable of mediating
biological actions that are IGF independent (Clemmons
1998; Spagnoli and Rosenfeld 1997; Rechler and Clemmons
1998). More recently, a family of IGFBP-related proteins
(IGFBP-rPs) has been identiﬁed that appear to have a 100-
fold lower afﬁnity for IGFs compared with IGFBPs. At
present, the functional roles of these IGFBP-rPs remains
elusive (Hwa et al. 1999). This study was undertaken to
characterize the cell membrane-bound binding sites for IGF-I
in human brain and pituitary gland.
Experimental procedures
Materials
Human recombinant [125I]IGF-I was obtained from Du Pont de
Nemours (Dreieich, Germany). [125I] standards and [3H] ultra ﬁlms
were obtained from Amersham Life Sciences (Amersham, Buck-
inghamshire, UK). IGF-I, Des1-3IGF-I and R3-IGF-I were pur-
chased from Gropep (Thebarton, Adelaide, Australia). Des1-3IGF-I
is truncated IGF-I, missing the ﬁrst three amino acids in the B
domain, and R3-IGF-I is an IGF-I analogue where the glutamate at
position 3 has been replaced by arginine.
Recombinant human IGFBP-3 and the monoclonal antibody
against the a-chain of human IGF-I receptor were purchased from
Upstate (Lake Placid, NY, USA). Biotinylated anti-chicken IgG was
obtained from Immuno Jackson Chemicals (Baltimore, MD, USA).
The polyclonal antibody against human IGFBP-3 was obtained from
Gropep (Thebarton, Adelaide, Australia). The polyclonal antibody
against human ALS was purchased from DSL (Webster, TX, USA).
Horseradish peroxidase (HRP)-streptavidin and HRP-conjugated
goat-anti-rabbit were obtained from Bio-Rad (San Francisco, CA,
USA). Normal rabbit serum was purchased from Zymed (San
Francisco, CA, USA).
The human hepatoma cell line HepG2 was a gift from D. Hoekstra
(Rijksuniversiteit Groningen, Groningen, the Netherlands). All cell
culture plastic ware was obtained from Costar (Cambridge, MA,
UKA). Dulbecco’s modiﬁed Eagle’s medium (DMEM) medium,
antibiotics, all reagents for reverse transcription and all primers were
from Life Technologies (Paisley, UK). Fetal calf serum was
purchased from Bodinco (Alkmaar, the Netherlands). The High
Fidelity PCR Master kit was obtained from Roche (Indianapolis, IN,
USA) and the RNeasy Mini Kit from Qiagen (Valencia, CA,
USA). All other chemicals were of the highest grade commercially
available.
Specificity of the antibodies
The antibody against human IGF-I receptor reacts speciﬁcally
against a 19-residue synthetic peptide corresponding to amino acid
residues 642–659 of the human IGF-I receptor a-subunit (Rosen-
weig et al. 1990). The polyclonal IGFBP-3 antibody used in this
study was obtained from rabbits immunized with a synthetic peptide
of unique sequence from the central domain of human IGFBP-3.
The speciﬁcity of the antibody was conﬁrmed using the antibody
preabsorbed with excess of matched recombinant human IGFBP-3.
Speciﬁcity of the immunoreactivity was also controlled by the
incubation of tissue sections in 5% goat serum instead of primary
antibodies; the immunohistochemical reactions were negative. For
western blotting experiments, non-speciﬁc staining was determined
by incubating parallel blots with non-immune rabbit serum instead
of the primary antibody solution (Fig. 4b).
For immunoprecipitation experiments, non-speciﬁc binding was
determined by incubating parallel blots with 3% bovine serum
albumin (BSA) instead of the primary antibody solution. The non-
speciﬁc binding of the anterior pituitary is shown in Fig. 5. The non-
speciﬁc bands for serum and other brain samples were the same (not
shown).
Tissues
Brains and pituitary glands were obtained from 10 patients without
neurological or psychiatric diseases (ﬁve men and ﬁve women aged
between 54 and 78 years). Pituitary glands and 0.5-cm thick blocks
of brain tissue were dissected at 0–4C, frozen rapidly by immersion
in isopenthane–dry-ice, and stored at ) 80C until used. Frontal
cortex and white matter was obtained from the frontal gyri and
cerebellum from one of the hemispheres. Care was taken to dissect
comparable regions from the different individuals. The choroid
plexus was obtained from the lateral ventricles. Post-mortem delay,
deﬁned as the time elapsed between death and freezing of the tissue
sections, ranged between 7 and 14 h. An ethical committee
approved the experiments on post-mortem brain.
[125I]IGF-I binding studies
Frozen tissue blocks were mounted on a cryostat chuck, coated with
embedding medium (OCT compound, Laboratory-Tek Products,
Ontario, Canada) and serial sections, 10-lm thick, were cut at
) 20C using a microtome-cryostat. Thereafter, sections were
mounted on gelatine-coated glass slides, and dried overnight under
vacuum. Sections were pre-incubated for 20 min at 20C in 25 mM
Tris/HCl (pH 7.4), containing 10 mM MgCl2, and 0.1% BSA. The
optimal conditions for the binding experiments have been described
previously (De Keyser et al. 1994).
For competition experiments sections were incubated for 90 min
with 0.1 nM [125I]IGF-I and increasing concentrations of compet-
itors IGF-I, DES(1-3)IGF-I, or R3-IGF-I. After incubation, the
sections were washed three times for 1 min in the same buffer, to
remove unbound ligand, and were then wiped from the slides using
Whatman GF/B glass ﬁbre ﬁlters. The level of radioactivity was
determined in a gamma-counter. Binding isotherms were estimated
by non-linear least-square curve ﬁtting. The inhibition constants (Ki
values) of IGF-I, DES(1-3)IGF-I and R3-IGF-I were calculated by
the method of Cheng and Prusoff (1973).
Autoradiographs were produced by incubating sections for
90 min at 20C with 0.1 nM [125I]IGF-I in the same buffer.
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Incubating consecutive sections with 0.5 lM IGF-I, or 0.5 lM
DES(1-3)IGF-I, or 0.5 lM R3-IGF-I assessed non-speciﬁc binding.
After incubation the sections were washed three times for 1 min in
the same buffer and quickly dipped in distilled water. The sections
were dried under a stream of cold air, placed in X-ray cassettes
together with commercially available [125I]-standards, and exposed
to [3H] ultra ﬁlms for 4 days. The ﬁlms were developed with a
Kodak D19 developer at 4C, and scanned with an Arcus plus
scanner. The images were digitized and analysed by computer-
assisted densitometry using NIH IMAGE analysis software. A
calibration curve was generated by ﬁtting of optical density and
disintegrations per minute per milligram polymer values of the [125I]
standards. The regions of interest were sampled, and mean optical
densities determined and converted into fmol/mg protein based on
the experimentally determined relation between polymer and brain
paste standards. Speciﬁc binding values were obtained by the
subtraction of non-speciﬁc binding images from corresponding total
binding images. All binding experiments were done in duplicate and
repeated twice.
Preparation of homogenates
Frozen tissue blocks of approximately 1 g were homogenized in
10 mL ice-cold Tris/HCl buffer (25 mM, pH 7.4) containing serine-,
cysteine-, aspartic- and metalloproteinase inhibitors, with an
Ultraturrax and Potter Elvehjem homogenizer, and centrifuged at
50 000 g for 15 min. The pellets, containing the cell membranes,
were resuspended in 10 mL of the same buffer as indicated above
and centrifuged twice at 50 000 g for 15 min. The ﬁnal pellet was
suspended in 1 mL of the same buffer containing 10% glycerol
(v/v), and stored at ) 80C. Protein concentrations were determined
by the method of Lowry et al. (1951). To be sure that there is no
blood contamination from the circulation, albumin was measured in
homogenates from the anterior and posterior pituitary gland by
using an albumin immune assay (BN2, Behring, Marburg,
Germany). In all the samples we used in this study, the albumin
fraction was not detectable.
Western immunoblotting and immunoprecipitation
For western immunoblotting experiments the homogenates were
diluted and resolved in sample buffer, and ran both under native
conditions [no sodium dodecyl sulphate (SDS), no mercaptoethanol
and no boiling], and reducing conditions (0.25% mercaptoethanol,
0.5% SDS and boiling during 6 min). Human IGFBP-3 was used as a
positive control and diluted in sample buffer containing 0.1% (w/v)
SDS. Sixty micrograms of sample protein and 10 lL (0.001 lg/lL)
human IGFBP-3 protein were loaded on the gel system and ran on
4–12% SDS–polyacrylamide gel electrophoresis (PAGE).
For immunoprecipitation experiments 50 lL of the homogenates
were rehomogenized in 200 lL ice-cold 50 mM Tris-buffer contain-
ing 6.25 mM EDTA, 1% Triton-X-100 (pH 7.4) and the same
protease inhibitors as indicated above. Homogenates were centri-
fuged at 3000 g for 10 min. Equal amounts of the supernatant
(200 lL) were diluted in 200 lL detergent buffer [50 mM EDTA,
50 mM Tris pH 7.4, 0.2% sodium deoxycholic acid (NaDOC),
0.05% non-idet P-40 (NP-40), 0.5% SDS]. The suspensions
(400 lL), 100 lL human serum (positive control for ALS) and
10 lL human IGFBP-3 (0.001 lg/lL) were then incubated with
5 lg polyclonal human IGFBP-3 antibody for 24 h at 4C. The
immunocomplexes were precipitated with agarose-G-beads at 4C
for 2 h. After washing, 3 times with low-salt washing buffer (50 mM
Tris-HCl, 0.05% NaDOC, 0.1% NP40, pH 7.4) and twice with
phosphate-buffered saline (PBS), the precipitated samples were
resuspended in sample buffer containing 0.1% SDS and boiled for
6 min. Fifty microlitres of the samples were loaded on the gel system
and separated under reducing conditions using 4–12% SDS–PAGE.
Proteins were transferred to nitrocellulose membranes and
incubated overnight at 4C with the primary antibody solution
[chicken anti-IGF-I receptor (1 : 500) or rabbit anti-IGFBP-3
(1 : 1000) and or rabbit anti-ALS diluted (1 : 1000)] in Tris-buffered
saline (TBS, pH 7.4) containing 0.5% milk powder. For the detection
of the IGF-I receptor, the membranes were incubated with
biotinylated second antibody solution (rabbit anti-chicken 1 : 600)
in TBS containing 0,5% milk powder, for 2 h at room temperature.
Finally, membranes were incubated with HRP-conjugated streptavi-
din (1 : 600) for 2 h at room temperature. For the detection of ALS
and IGFBP-3, membranes were incubated with HRP-conjugated goat
anti-rabbit solution (1 : 1000) in TBS containing 0.5% milk powder,
for 2 h at room temperature. The complexes derived from western
immunoblotting and immunoprecipitation experiments were visual-
ized using freshly prepared diaminobenzidine (DAB, 30-mg/100 mL
Tris buffer, pH 7.4 and 0.015% H2O2), and the opti-(4-chloro-1-
naphthol) 4 CN staining method of Bio-Rad. Between all steps the
nitro-cellulose membrane was rinsed in TBS for 30 min.
Immunohistochemical experiments
Frozen sections, 10-lm thick, were pre-incubated in 25 mM
Tris/HCl (pH 7.4) containing 10 mM MgCl2. Sections that were
and were not pre-incubated were ﬁxated for 15 min in 3% buffered
formaldehyde and washed in PBS for 10 min. To exhaust
endogenous peroxidase activity, sections were immersed for
10 min in 0.3% H2O2 in PBS prior to the ﬁrst antibody incubation.
Before the addition of ﬁrst and secondary antibody solution,
sections were incubated for 30 min at room temperature in normal
goat serum to suppress non-speciﬁc antibody binding. Thereafter,
sections were incubated in primary antibody solution: rabbit anti-
IGFBP-3 (1 : 200) in PBS for 24 h at 4C. Sections were then
incubated with the secondary biotinylated antibody solution: goat
anti-rabbit (1 : 200) in PBS for 120 min at room temperature.
Finally, sections were incubated in HRP-conjugated streptavidin
solution (1 : 200) in PBS for 90 min at room temperature and
processed by the diaminobenzidine/H2O2 reaction (30 mg DAB/
100 mL Tris buffer, pH 7.4) and 0.01% H2O2 and they were
counterstained with 3% haematoxylin. Between all steps the
sections were rinsed thoroughly with PBS.
RT-PCR
HepG2 cells were cultured in DMEM supplemented with 10% fetal
calf serum, 50 U/mL penicillin, and 50 lg/mL streptomycin in a
humidiﬁed 5% CO2 atmosphere at 37C. Total RNA was isolated
from either frozen anterior pituitary tissue (100 mg/sample) or
HepG2 cells (107 cells/sample) using the RNeasy Mini Kit and
following the manufacturers’ instructions. Single-stranded cDNA
was synthesized from 5 lg total RNA using 2.5 lg Oligo (dT)12)18
primer, 1000 units SuperscriptTM RT II, 20 lL ﬁrst strand buffer,
10 mM dithiothreitol (DTT) and 0.5 mM dNTP in a total volume of
100 lL. The RNA sample and the Oligo (dT) primer were denatured
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at 65C for 15 min and placed on ice for 5 min before addition to
the reaction tube. Reverse transcription was performed for 1 h at
37C, and subsequently the samples were heated to 99C for 5 min
to terminate the reaction. PCR was performed with the High Fidelity
PCR Master using 5 lL of the obtained cDNA and 7.5 pmol sense
and antisense primer, according to the manufacturers’ instructions.
The ﬁnal reaction volume was 50 lL. The tubes were incubated in a
GeneAmp PCR System 9700 (Perkin-Elmer, Norwalk, CT, USA) at
94C for 5 min to denature the cDNA and primers. The cycling
programme was 94C for 30 s, 55C for 30 s, 72C for 30 s for actin
and 94C for 30 s, 57C for 30 s, 72C for 50 s (7 min in the last
cycle) for ALS. For each primer set and sample, an increasing
number of PCR cycles (25–40) was performed with otherwise ﬁxed
conditions. The following primers were employed: actin: 5¢-AACA-
CCCCAGCCATGTAC-3¢ (sense) and 5¢-ATGTCACGCACGATTT-
CC-3¢ (antisense, 254 bp ampliﬁed product) and ALS 5¢-CTCAAC-
CTCGGCTGGAATAG-3¢ (sense) and 5¢-CACAGGCTCTGCTCC-
TCAAT-3¢ (antisense, 770 bp ampliﬁed product). In each experi-
ment, water, RNA and cDNA alone, as well as cDNA with only
sense or antisense primer, was used as a negative control to check
for contamination and speciﬁcity. Ten microlitres of PCR products
were separated on 2.0% agarose gels, stained with ethidium
bromide, and photographed using a Polaroid DS34 Instant Screen
Direct Camera (Hertfordshire, UK).
Results
[125I]IGF-I binding
We ﬁrst studied the IGF-I binding sites in human brain and
pituitary gland by using radioligand binding techniques with
[125I]IGF-I and autoradiography. Before incubation with
[125I]IGF-I tissue slices were pre-incubated in buffer to
remove endogenous IGFs and other soluble proteins. On
adjacent tissue sections of frontal cortex (Fig. 1), cerebellum,
choroid plexus, anterior and posterior pituitary, we performed
[125I]IGF-I competition binding experiments with IGF-I,
DES(1-3)IGF-I and R3-IGF-I. Both, DES(1-3)IGF-I and
R3-IGF-I bind to IGF-I receptors but have low afﬁnity for
IGFBPs (Ballard et al. 1987; Szabo et al. 1988; Tomas et al.
1991).
In all brain regions and choroid plexus, [125I]IGF-I was
equally displaced by IGF-I, DES(1-3)IGF-I, and R3-IGF-I
(Fig. 1). The curves were best ﬁtted to a single-site-binding
model. The mean Ki values ± SD were 1.0 ± 0.3 nM for
IGF-I, 1.1 ± 0.2 nM for DES(1-3)IGF-I, and 1.2 ± 0.2 nM
for R3-IGF-I [p ¼ 0.74 (Mann–Whitney U-test)]. In contrast,
in the anterior pituitary, there was no displacement of
[125I]IGF-I binding with DES(1-3)IGF-I and R3-IGF-I, and
IGF-I had a 10-fold lower afﬁnity [Ki ¼ 12.7 ± 1.5 nM,
p < 0.0001 (Mann–Whitney U-test)] for this binding site
than in brain regions and choroid plexus (Fig. 1).
We then compared autoradiographs obtained following
incubation with [125I]IGF-I in the absence and presence of
0.5 lM IGF-I, 0.5 lM DES(1-3)IGF-I, or 0.5 lM R3-IGF-I.
As shown in Fig. 2, binding of [125I]IGF-I was equally
displaced by all three competitors in cerebellum (not shown),
frontal cortex, cerebral white matter, choroid plexus (not
shown), and posterior pituitary. In the anterior pituitary
(Fig. 2), [125I]IGF-I binding was displaced by IGF-I, but not
by DES(1-3)IGF-I or R3-IGF-I, indicating that [125I]IGF-I
labelled an IGF-binding site that was different from the IGF-I
receptor. Non-speciﬁc binding of competition and autoradio-
graphic experiments in the presence of IGF-I varied between
30 and 40% of the total binding. [125I]IGF-I binding
characteristics were not different between males and females.
IGF-I receptor concentrations are shown in Table 1.
IGF-I receptor and IGFBP-3-binding in homogenates
from human pituitary and brain regions
To further examine the nature of the IGF-I binding site in the
anterior pituitary, we performed western immunoblot analy-
sis and immunoprecipitation using a monoclonal antibody
against the human IGF-I receptor, and polyclonal antibodies
against human IGFBP-3 and ALS. The antibody against
Fig. 1 Representative competition binding curves of IGF-I (s),
DES(1-3)IGF-I (.) and R3-IGF-I (h) to 0.1 nM [125I]IGF-I on micro-
tome sections of human frontal cortex (a) and anterior pituitary (b).
Computer analysis of the binding data revealed that the competition
curves were best described by a one-component binding model. In
frontal cortex, [125I]IGF-I was equally displaced by IGF-I, DES(1-3)
IGF-I and R3-IGF-I. Ki values were 0.9 nM for IGF-I and DES(1-3)
IGF-I, and 1.0 nM for R3-IGF-I. In the anterior pituitary [125I]IGF-I was
displaced by IGF-I (Ki value of 12 nM) but not by DES(1-3)IGF-I and
R3-IGF-I.
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human IGF-I receptor reacts speciﬁcally against a 19-residue
synthetic peptide corresponding to amino acid residues 642–
659 of the human IGF-I receptor a-subunit (Rosenweig et al.
1990). In frontal cortex, choroid plexus, cerebellum, white
matter, and posterior pituitary a double band of 118 kDa
corresponding to the a-chains (LeRoith et al. 1995) of the
IGF-I receptor were identiﬁed (Fig. 3). In the anterior lobe of
the pituitary gland no reaction with anti-human IGF-I
receptor was found (Fig. 3).
Western blotting was performed under different conditions.
In the ﬁrst approach pellet fractions of the anterior pituitary
ran under denaturing and reducing conditions, and were
stained for IGFBP-3. A single band of 40 kDa (Fig. 4a) was
detected under these conditions. When the same samples ran
under native conditions, and were stained for IGFBP-3 they
revealed one band of 150 kDa (Fig. 4a). Puriﬁed IGFBP-3
was used as a positive control. With anti-IGFBP-3 we found
one band of 40 kDa (Fig. 4a). Non-immune rabbit serum was
used to determine the non-speciﬁc binding (Fig. 4b).
We performed immunoprecipitation experiments to visu-
alize the components of the complex. Immunocomplexes of
proteins with anti-IGFBP-3, revealed a band of approxi-
mately 40 kDa in anterior pituitary, posterior pituitary and
frontal cortex, just as human IGFBP-3 that was used as
a positive control (Fig. 5). Homogenates of the anterior
pituitary immunoprecipitated with anti-IGFBP-3 and stained
with anti-ALS revealed a 86-kDa band. The same band was
present in human serum that contains ALS and was used as a
positive control. This was not observed in the frontal cortex
and the posterior pituitary (Fig. 5). Thus these results showed
the presence of an IGFBP-3-ALS complex in the anterior
pituitary. This complex was absent in the posterior pituitary
and frontal cortex.
IGFBP-3 binding to cell membranes
To conﬁrm the presence of IGFBP-3 in the anterior pituitary,
we performed immunohistochemistry both with and without
Fig. 2 Autoradiographs of 0.1 nM [125I]IGF-I binding in the absence ¼
total binding (i) and the presence of 0.5 lM unlabelled IGF-I ¼ non-
specific binding (ii), or 0.5 lM DES(1-3)IGF-I (iii), or 0.5 lM R3-IGF-I
(iv) to microscope slide-mounted sections of frontal cortex (a) and
pituitary gland (b). In frontal cortex (co), white matter (wm), and pos-
terior pituitary (pp) [125I]IGF-I was equally displaced with IGF-I,
DES(1-3) IGF-I and R3-IGF-I. In the anterior pituitary (ap), [125I]IGF-I
was displaced with IGF-I, but not with DES(1-3)IGF-I and R3-IGF-I.
Scale bar ¼ 1 cm.
Table 1 IGF-I receptor concentrations labelled by [125I]IGF-I in human
adult brain samples and pituitary gland in fmol/mg
Region Male (n ¼ 5) Female (n ¼ 5) p*
Frontal cortex 24.6 ± 2.7 23.6 ± 3.7 0.84
Frontal white matter 8.4 ± 1.8 9.4 ± 2.7 0.69
Cerebellum
Granule cell layer 12.6 ± 2.1 13.8 ± 4.2 0.84
Molecular layer 36.4 ± 5.7 38.2 ± 6.7 0.42
Deep white matter 9.0 ± 1.8 10.7 ± 3.0 0.39
Dendate nucleus 17.6 ± 2.7 20.0 ± 5.3 0.42
Choroid plexus 46.4 ± 8.1 43.4 ± 4.9 0.42
Pituitary gland
Anterior lobe ND ND –
Posterior lobe 23.8 ± 3.6 21.6 ± 2.7 0.42
Slide-mounted tissue sections were incubated with 0.1 nM [125I]IGF-I.
Autoradiograms were generated by exposing the slide-mounted tissue
sections to [3H] ultra film for 4 days, and subsequently quantified by
computerized densitometry. Non-specific binding was determined in
the presence of DES(1-3)IGF-I and or R3-IGF-I. ND; not detected.
Data are the mean ± SD. *Mann–Whitney U-test.
Fig. 3 Western immunoblot of brain samples and pituitary samples
ran on 7.5% SDS–PAGE under reducing conditions using an antibody
against the a-chains of the human IGF-I receptor. Bands were visu-
alized using DAB. We found two bands of approximately 118 kDa
corresponding to the a-subunits of IGF-I receptor into detergent-
solubilized total cell membrane fraction (60 lg) of frontal cortex (a),
choroid plexus (b), cerebellum (c), posterior pituitary gland (d) and
cerebral white matter (f). We found no expression of IGF-I receptor
a-subunits in pellet fractions of the anterior pituitary (e).
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pre-incubation in 25 mM Tris-buffer supplemented
with 10 mM MgCl2, using a polyclonal antibody against
IGFBP-3. Without pre-incubation, IGFBP-3 was present in
the anterior and posterior pituitary, and in the frontal cortex
(Fig. 6). IGFBP-3 was located in anterior pituitary cells and
in the posterior pituitary; IGFBP-3 was located in the
pituicytes. In the brain regions, IGFBP-3 was located in
neurons. Following pre-incubation in 25 mM Tris-buffer
supplemented with 10 mM MgCl2, IGFBP-3 was no longer
detectable in the posterior pituitary and any of the brain
regions, but was still present in the anterior pituitary.
ALS mRNA expression in anterior pituitary
In order to prove whether the ALS protein found in the
anterior pituitary derives from the anterior pituitary itself or
from the circulation, we performed RT-PCR on frozen
anterior pituitary tissue of three patients. To date, it has not
been shown that blood cells produce ALS. However, as it is
not possible to wash tissue extensively before RNA isolation,
we also tested samples of freshly isolated blood cells to
exclude any possibility that mRNA of blood cells may falsify
the results. The human hepatoma cell line HepG2 was used a
positive control as it is known that ALS is highly expressed
Fig. 5 Immunoprecipitation of proteins with anti-IGFBP-3 in anterior
pituitary (ap), posterior pituitary (pp), frontal cortex (co), human
IGFBP-3 (BP3) and serum (ser). Bands were visualized using opti-4-
CN. Immunocomplexes stained for IGFBP-3 (a) showed one band of
40 kDa in anterior pituitary (ap), posterior pituitary (pp), frontal cortex
(co) and for IGFBP-3 used as a positive control (BP3). Immunocom-
plexes stained for ALS (b) showed a single band of 86 kDa in anterior
pituitary (ap) and serum (ser), but not in the posterior pituitary (pp) and
frontal cortex (co). Non-specific bands (nsb) of the anterior pituitary are
shown using BSA instead of the primary antibody.
Fig. 4 Western immunoblots of anterior pituitary samples ran on 12%
SDS–PAGE both under native conditions, and under reducing and
denaturing conditions. Samples were stained for IGFBP-3 (a). Sam-
ples ran under native conditions revealed a 150-kDa-band (i) and
samples that ran under reducing conditions revealed a single band of
40 kDa (ii). Human IGFBP-3 was used as a positive control and
presents one band of 40 kDa (iii). In (b), non-specific binding was
determined by incubating parallel blots with non-immune rabbit serum
instead of anti-IGFBP-3. Samples ran under native conditions (i),
denatured conditions (ii), and pure IGFBP-3 (iii) did not reveal
non-specific bands. Protein marker is shown at the left. Bands were
visualized using opti-4 CN.
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in liver (Scott and Baxter 1991). Furthermore, actin mRNA
levels were used to standardize RNA contents of different
samples.
The results show that ALS mRNA is detectable in the
positive control HepG2 cells and the anterior pituitary
(Fig. 7). When comparing the relative band intensities, the
ALS mRNA level in the anterior pituitary ranged between
20% and 30% of the level in HepG2 cells. No speciﬁc signal
for the ALS mRNA fragment was detected in the blood cell
samples. The bands seen in blood cell samples are of smaller
size and, therefore, are non-speciﬁc. This rules out ALS
mRNA in the anterior pituitary being derived from contami-
nation with blood.
Discussion
IGF-I binding sites are widely distributed throughout the
human brain and pituitary gland (De Keyser et al. 1994). The
brain contains not only IGF receptors but also the six
different IGFBPs that have been identiﬁed (Spagnoli and
Rosenfeld 1997; Rechler and Clemmons 1998). These
IGFBPs are soluble proteins, and we showed that pre-
incubation in a buffer solution (Tris/HCl containing 10 mM
MgCl2) readily abolished both the autoradiographic labelling
Fig. 7 RT-PCR was performed with RNA isolated from anterior pitui-
tary tissue of three patients, blood cells and HepG2 cells. The PCR
products were separated on a 2% agarose gel. One representative
ethidium bromide-stained gel is shown. The amplified ALS fragment
(770 bp) was detected in HepG2 cells (lanes 1 and 2) and anterior
pituitary tissue (lanes 3 and 4) after 35 and 40 cycles but not in whole
blood (lanes 5 and 6). Comparable amounts of the amplified actin
fragment (254 bp, internal control) were detected in HepG2 cells
(lane 7), anterior pituitary tissue (lane 8), and whole blood (lane 9)
after 35 cycles. Names of the genes are indicated on the left and the
corresponding fragment sizes on the right. H, HepG2 cells; p, anterior
pituitary; b, blood cells.
Fig. 6 Photomicrographs of IGFBP-3
immunohistochemistry in anterior (a, b) and
posterior pituitary gland (c, d) and frontal
cortex (e, f). Nuclei are counterstained with
haematoxylin (dark blue). Prior to pre-incu-
bation in Tris-buffer containing MgCl2,
IGFBP-3 was present on cells in anterior (a)
and posterior pituitary (c), and on neurones
in frontal cortex (e). After pre-incubation,
expression of IGFBP-3 was no longer
detectable in posterior pituitary (d) and in
frontal cortex (f). In contrast, IGFBP-3 was
still present on cells in anterior pituitary (b).
Scale bars ¼ 100 lm.
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and immunohistochemical visualization of IGFBPs in slices
of different brain regions (Wilczak et al. 2000). The binding
characteristics of [125I]IGF-I in the brain regions and
posterior pituitary were compatible with binding to IGF-I
receptors.
In the anterior pituitary, [125I]IGF-I binding occurred to a
binding site with a 10-fold lower afﬁnity than the IGF-I
receptor. Using western immunoblotting experiments with
anti-IGFBP-3 under native conditions, we identiﬁed this
binding site as a 150-kDa IGFBP-3-containing molecule. In
this region, pre-incubation in buffer did not abolish IGFBP-3
immunoreactivity, indicating that this IGFBP-3-containing
complex was tightly bound to the cell membranes. Addi-
tionally to these ﬁndings IGFBP-3 was completely com-
plexed with ALS because we found no smaller proteins with
anti-IGFBP-3. In contrast, when the same samples were
analysed under high reducing and denaturing conditions, we
identiﬁed a single 40-kDa IGFBP-3 band. Under these
conditions the 150-kDa complex was dissociated.
Immunoprecipitation experiments conﬁrmed the presence
of a 150-kDa complex in the anterior pituitary. When proteins
of the anterior pituitary were complexed with anti-IGFBP-3
and these immunocomplexes were stained for IGFBP-3, they
showed one band of approximately 40 kDa, and when stained
for ALS they showed an 86-kDa band. Immunocomplexes
from the posterior pituitary and frontal cortex which were
stained for ALS did not reveal an 86-kDa band, indicating the
absence of ALS. When these immunocomplexes were stained
for IGFBP-3, they revealed a band of approximately 40 kDa,
indicating the presence of IGFBP-3 in both anterior and
posterior pituitary and frontal cortex.
It has been shown previously that IGFBP-3 has cellular
effects that are independent of IGF presence or action, and
these effects are mediated by binding of IGFBP-3 to the cell
surface, possibly to speciﬁc receptors (Mohseni-Zadeh and
Binoux 1997; Young Lee and Rechler 1995; Rechler and
Clemmons 1998). However, since IGF-I in association with
IGFBP-3 prevents binding of IGFBP-3 to the cell membrane
(Smith et al. 1992), the IGFBP-3 binding site in the anterior
pituitary must be of a different composition.
The molecular weight of IGFBP-3 in its non-glycosylated
form is 29 kDa, in its glycosylated state 40–44 kDa, and
when it forms a complex with ALS, 140–150 kDa (Martin
and Baxter 1992; Spagnoli and Rosenfeld 1997). IGFBP-3 is
the predominant carrier protein of IGF-I in serum. The IGF-I–
IGFBP-3 dimer forms a complex with ALS, and this ternary
complex prolongs the serum half-live of IGF-I by many
hours (Jones and Clemmons 1995; Spagnoli and Rosenfeld
1997; Rechler and Clemmons 1998). Once released from the
complex, IGF-I leaves the circulation and enters target tissues
with the aid of IGFBPs present on the cell surface or in the
extracellular matrix.
By using RT-PCR in anterior pituitary and blood samples,
we found the expression of ALS mRNA in the anterior
pituitary but not in blood samples. Thus, our ﬁndings suggest
that the human anterior pituitary gland expressed ALS
mRNA and ALS protein and this ALS forms a complex with
IGFBP-3 bound to the cell membrane. ALS is mainly
synthesized by the liver, and the native ALS molecule
appears in serum as a 84–86-kDa glycoprotein doublet
(Baxter 1988; Baxter and Martin 1989; Baxter et al. 1989;
Scott and Baxter 1991). Interestingly, it has been shown that
follicular ﬂuid ALS originates from the ovary and that ALS
is also synthesized by the kidney (Dai and Baxter 1994;
Wandji et al. 2000).
We were unable to detect IGF-I receptors in the anterior
pituitary gland in this study. However, our in situ observa-
tions do not entirely exclude their presence in vivo. IGF-I
receptor mRNA has been demonstrated by in situ hybridiza-
tion in rodent anterior pituitary slices and cell cultures (Bach
and Bondy 1992; Oomizy et al. 1998). It might be possible
that the receptors were down-regulated by IGF-I, as has been
shown for IGF-I receptors in rat pituitary cells (Yamamoto
et al. 1993).
In conclusion, our ﬁndings show that in human anterior
pituitary gland IGF-I binds to a not previously reported
tightly membrane-bound IGFBP-3–ALS complex. The func-
tional implication of the binding of IGF-I to this complex
requires further experimentation at the cellular level.
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